-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RHFd+AyF4mqpbRqJlNfL1jhpV3DhQMS084w8+bYGOT71OI2aze1CxC7PGSWQv27Q LViNVd+Z87Uz5+e1k+wi3Q== 0001144204-08-030309.txt : 20080516 0001144204-08-030309.hdr.sgml : 20080516 20080516134555 ACCESSION NUMBER: 0001144204-08-030309 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080331 FILED AS OF DATE: 20080516 DATE AS OF CHANGE: 20080516 EFFECTIVENESS DATE: 20080516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Huifeng Bio-Pharmaceutical Technology, Inc. CENTRAL INDEX KEY: 0001119951 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 870650264 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32253 FILM NUMBER: 08841469 BUSINESS ADDRESS: STREET 1: 409 CALLE SAN PABLO SUITE 100-101 CITY: CAMARILLO STATE: CA ZIP: 93010 BUSINESS PHONE: 805-484-7687 MAIL ADDRESS: STREET 1: 409 CALLE SAN PABLO SUITE 100-101 CITY: CAMARILLO STATE: CA ZIP: 93010 FORMER COMPANY: FORMER CONFORMED NAME: SECURED DATA INC /NV/ DATE OF NAME CHANGE: 20021115 FORMER COMPANY: FORMER CONFORMED NAME: ENTERNET INC DATE OF NAME CHANGE: 20000721 NT 10-Q 1 v114953_nt10q.htm Unassociated Document
SECURITIES & EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 12b-25

Notification of Late Filing

HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC.
 
Commission File Number 000-32253
(Check one)
o Form 10-K o Form 10-KSB o Form 11-K o Form 20-F
 
x Form 10-Q o Form 10-QSB o Form N-SAR  o Form N-CSR
 
For the period ended: March 31, 2008
 
o Transition Report on Form 10-K and Form 10-KSB

o Transition Report on Form 20-F

o Transition Report on Form 11-K

o Transition Report on Form 10-Q and Form 10-QSB

o Transition Report on Form N-SAR

For the transition period ended:
___________
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I
REGISTRANT INFORMATION

Full name of Registrant
HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC.
 
 

Former name, if applicable

16B/F Ruixin Road Bldg. No. 25 Gaoxin Road Xi An 710075 Shaanxi Province, China

Address of principal executive office

 
 

 
 
PART II

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
o (a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
(b)
The subject annual report, semi-annual report, transition report on Form 10-K 10-KSB, 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, 10-QSB,or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
 
o (c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III
NARRATIVE
 
Certain financial and other information necessary for an accurate and full completion of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 could not be provided within the prescribed time period without unreasonable effort or expense.

PART IV
OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Jing’an Wang
86
29 8824 6358
Name
Area code
Telephone Number

(2) Have all other periodic reports required under Section 13 or 15(d) or the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed.
Yes x No o
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof. Yes o  No x
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 
 

 
 
HUIFENG BIO-PHARMACEUTICAL TECHNOLOGY, INC.
______________________________________________
Name of Registrant as Specified in its Charter

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 
Date: May 14, 2008 By: /s/ Jing’an Wang
    Jing’an Wang
    Chief Executive Officer
     
 
 

 
 
 


-----END PRIVACY-ENHANCED MESSAGE-----